
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 18, 2026, 8:05 AM ET
INOVIO submitted a Conditional Marketing Authorization application to the European Medicines Agency for VOCERYQ in adults with recurrent respiratory papillomatosis.
Nasdaq: $INOVOCERYQ (INO-3107) · FDA approvedAccelerated approval · October 30, 2026Offering closed · November 9, 2026
INO Stock Hub: INOVIO Pharmaceuticals News, VOCERYQ FDA Approval and Financing
On October 30, 2026 the FDA granted accelerated approval to VOCERYQ (INO-3107) for adults with recurrent respiratory papillomatosis, INOVIO’s first approved product; the approval rests on a reduction in the frequency of surgery and requires post-approval trials to confirm clinical benefit. The underwritten offering priced November 5 closed on November 9: 69,461,520 common shares at $1.05, including the 10,714,285 option shares, and 12,681,337 pre-funded warrants at $1.049, for about $80.5 million of net proceeds. Third-quarter results released November 10 report cash, cash equivalents and short-term investments of $48.4 million at September 30, before the offering, and a quarterly net loss of $49.2 million that includes a $26.9 million non-cash warrant revaluation loss; shares outstanding were 187,306,884 on November 10. INOVIO expects its resources to fund operations into late Q4 2027, while the Form 10-Q keeps substantial doubt about continuing as a going concern beyond the fourth quarter of 2027. The favorable $80.4 million VGXI judgment carries collection and appeal risk; it is not cash available for a launch.
Research Library
The complete INO research report
58 pages · Research updated November 10, 2026 · Dated edition
Next company milestones
By year-end 2026 · VOCERYQ ordering and confirmatory protocol; EMA application submitted November 18
INOVIO released third-quarter 2026 results on November 10 and held its conference call and webcast that day. The company expects VOCERYQ to be available to order and ship approximately 60 days from the October 30 approval date, with full field deployment in the first quarter of 2027; it expects to submit a draft confirmatory-study protocol to the FDA by the end of 2026, aiming to align on a final protocol by mid-2027. These are company expectations, not completed events. On November 18, 2026 INOVIO announced that it has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ in adults with RRP, ahead of its year-end plan; submission is not approval, and the EMA review lies ahead. EMA submission release → · Q3 results release → · Form 8-K, exhibit 99.1 →
The offering priced on November 5 closed on November 9, 2026, according to the Q3 Form 10-Q, with net proceeds of approximately $80.5 million; full terms are in chapter 10. Q3 Form 10-Q → · Company pricing announcement → · Final prospectus supplement →
Completed on October 30, 2026: the FDA approved VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for the treatment of adults with recurrent respiratory papillomatosis, the first plasmid DNA-based immunotherapy for the disease. In the open-label trial, 7 of the 26 adults with at least three surgeries in the prior year (27%) needed no surgical intervention in the first year after treatment. FDA announcement →
What comes next: INOVIO says current inventory and capacity should support at least the first year of launch through 2027 and that it is seeking partners for other pipeline candidates. Its cash guidance runs into late Q4 2027 and excludes VOCERYQ revenue expected from 2027. Pricing, access and funding remain execution tests. Q3 results release. Next dated investor event: a fireside chat at the Piper Sandler 38th Annual Healthcare Conference in New York on Tuesday, December 1, 2026, 2:00–2:25 p.m. ET, with a webcast replay available for 90 days, according to the company. The presentation at the Jefferies Global Healthcare Conference in London was scheduled for Wednesday, November 18, 2026, at 12:00 p.m. ET (5:00 p.m. GMT). Conference appearances are not data releases. Company release.
INO stock: dated key data
Chart analysis · JC
Technical chart analysis of $INO with bull and bear scenarios on JC Just Charts.
Cash and investments · Sept. 30
$48.4M
Cash, cash equivalents and short-term investments in the Q3 Form 10-Q, before about $80.5M of net proceeds from the offering closed November 9 and $10.9M of warrant-exercise proceeds after September 30. $36.7M at June 30.
Nine-month operating cash use
$54.9M
Nine months ended September 30, 2026; Q4 2026 operational net cash burn estimated by the company at about $21.0M.
Shares outstanding
187,306,884
November 10, 2026, on the cover of the Q3 Form 10-Q; 110,181,507 at September 30, 2026, before the offering closed November 9 (Q3 Form 10-Q).
November net proceeds
~$80.5M
Offering closed November 9, 2026; not included in the September 30 balance.
Warrant shares outstanding
94.081M
September 30, 2026, five warrant issues from December 2024 to July 2026, with exercise prices from $1.10 to $3.76; potential shares, not issued common stock.
RRP-001 participants
32 adults
Single-arm trial; no concurrent randomized control.
September 30 cash, nine-month cash use, offering closing and November 10 share count: Q3 Form 10-Q and Q3 results release; earlier September 30 estimate: November 5 Form 8-K; September 30 and post-offering shares: November 6 final prospectus supplement; financial, regulatory and June share data: June Form 10-Q; July financing: July 31 Form 8-K; Nasdaq historical quotes; trial design: RRP-001 registry. Historical potential warrant shares are distinct from issued common shares.
INO today: VOCERYQ approval, launch and the funding clock
The FDA decision settled the accelerated-approval eligibility question: on October 30, 2026 the agency granted accelerated approval to VOCERYQ (INO-3107) for adults with recurrent respiratory papillomatosis (RRP). The approval is based on an intermediate endpoint, the reduction in surgical procedures, judged reasonably likely to predict clinical benefit; INOVIO must run post-approval trials to confirm it. FDA announcement.
Net proceeds of approximately $80.5 million from the offering that closed November 9 (pricing, share counts and option exercise in the catalyst calendar and chapter 10) are intended mainly for VOCERYQ launch costs, development and general corporate uses. The offering documents cite an expected VOCERYQ price of $115,000 per dose (about $460,000 for the four-dose series) and an application for conditional European marketing authorization before the end of 2026; INOVIO announced on November 18, 2026 that the application has been submitted to the EMA (EMA submission release). Company pricing release · Final prospectus supplement · Q3 Form 10-Q.
Third-quarter 2026 results, released on November 10: revenue from collaborative arrangements of $0.3 million; R&D expenses of $10.6 million (versus $13.3 million a year earlier) and SG&A of $9.2 million (versus $7.9 million), the increase tied to the planned VOCERYQ launch; a net loss of $49.2 million, or $0.50 per share, including a $26.9 million non-cash loss on the fair value of warrant liabilities. Cash, cash equivalents and short-term investments were $48.4 million at September 30, against $58.5 million at December 31, 2025, and operating activities used $54.9 million in the first nine months. INOVIO estimates that current resources, including the approximately $80.5 million of net offering proceeds, $10.9 million from warrant exercises after September 30 and an operational net cash burn of about $21.0 million in the fourth quarter of 2026, will support operations into late Q4 2027; the projection excludes VOCERYQ revenue and any further capital raising. The Form 10-Q states that substantial doubt exists about continuing as a going concern beyond the fourth quarter of 2027. Q3 results release · Q3 Form 10-Q.
The November 6 final prospectus supplement had already moved the runway estimate into the late fourth quarter of 2027, replacing the August forecast of late Q1 2027. The estimate rests on assumptions that may prove incorrect. Launch spending and confirmatory work are still to be executed. Runway estimate and going-concern statement · August liquidity disclosure.
Main risk: The offering closed on November 9 and the company guides to funding into late Q4 2027, but the Form 10-Q keeps substantial doubt about continuing as a going concern beyond that point, and the guidance excludes VOCERYQ revenue. Shares outstanding reached 187,306,884 on November 10 from 110,181,507 at September 30, before exercise of the 12,681,337 pre-funded warrants, other warrants and equity awards, and approval does not guarantee commercial uptake, affordable launch execution or favorable financing.
Constructive case
The FDA accepted the evidence package and granted accelerated approval, giving INOVIO its first product and a nonsurgical option in adult RRP, and the offering that closed November 9 adds about $80.5 million of net proceeds, which the company expects to fund operations into late Q4 2027. The conditional marketing authorization application submitted to the EMA on November 18 opens a possible European path, subject to review. Actual prescribing, reimbursement, launch execution and financing terms will determine whether the approval becomes revenue.
Cautious case
PAPZIMEOS is already approved for adult RRP, the approval depends on confirmatory trials, and the efficacy evidence comes from 26 adults in an uncontrolled study. Pricing at $115,000 per dose, launch costs, the funding shortfall described in the offering documents before closing and 94.1 million warrant shares outstanding at September 30 can still affect existing shareholders after approval.
INO stock news: six selected updates
Nov 18, 2026
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ
INOVIO submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with recurrent respiratory papillomatosis (RRP). The FDA granted VOCERYQ accelerated approval on October 30, 2026 for adults with RRP to reduce the frequency of surgery. The European Commission granted Orphan Drug designation to INO-3107 in 2023, and it received Advanced Therapy Medicinal Product (ATMP) Certification from the EMA's Committee for Advanced Therapies.
Nov 17, 2026
Inovio Pharmaceuticals appoints Jeffrey Libson to board, expanding it to nine directors
Effective November 13, 2026, Inovio Pharmaceuticals increased its Board from eight to nine directors and appointed Jeffrey Libson to fill the new seat. Libson was also appointed to the Finance Committee and will receive an annual cash retainer of $45,000 as a Board member plus $5,000 for Finance Committee service. He has been a mentor and strategic advisor to the Company since January 2025 and previously was a partner at Cooley LLP.
Nov 11, 2026
Piper Sandler lowers Inovio price target to $6 from $8
Piper Sandler reduced its price target on Inovio Pharmaceuticals to $6 from $8. No other details are available. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 11, 2026
INOVIO to Participate in Upcoming Investor Conferences
INOVIO will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 18, with a presentation and webcast. It will also take part in the Piper Sandler 38th Annual Healthcare Conference in New York on Tuesday, December 1, in a fireside chat. Management will hold one-on-one meetings with investors during these conferences, and replays will be available for 90 days.
Nov 10, 2026
INOVIO reports third quarter 2026 financial results and recent business highlights
INOVIO reported a net loss of $49.2 million, or $0.50 per basic and diluted share, for the three months ended September 30, 2026. R&D expenses decreased to $10.6 million, while SG&A expenses increased to $9.2 million due to the anticipated launch of VOCERYQ. Cash, cash equivalents and short-term investments were $48.4 million as of September 30, 2026, excluding net proceeds of approximately $80.5 million from the November 2026 offering. The company estimates its cash will support operations into late fourth quarter 2027.
Nov 6, 2026
Inovio prices $75 million underwritten public offering at $1.05 per share
Inovio priced an underwritten public offering of 58,747,235 common shares at $1.05 per share and pre-funded warrants for 12,681,337 shares at $1.049 per warrant. Gross proceeds are expected to be approximately $75 million, and underwriters hold a 30-day option for up to 10,714,285 more shares. Closing is expected on or about November 9, 2026. Third quarter 2026 results are due November 10, 2026. Reported by the press from an official company announcement; the primary document was not yet available in our sources at the time of writing.
INO stock catalysts: dated milestones
- October 30, 2026 · VOCERYQ accelerated approvalCompleted · FDA decision
The FDA approved VOCERYQ (INO-3107) for adults with recurrent respiratory papillomatosis, with post-approval trials required to verify clinical benefit. FDA announcement.
- November 5–9, 2026 · Offering priced and closedCompleted · closed November 9 · about $80.5 million net with the option shares
Full terms are in chapter 10. The November 6 final prospectus supplement puts shares outstanding at 168,928,742 after the offering, before the underwriters’ option shares, and dilution at $0.47 per share for buyers. On November 6 the underwriters exercised the option in full; the November 9 Form 8-K puts expected net proceeds at about $80.5 million, and the Q3 Form 10-Q confirms the closing on November 9, 2026. Q3 Form 10-Q · Official pricing release · November 9 Form 8-K · Final prospectus supplement.
- November 10, 2026 · Q3 2026 results and conference callCompleted · results released; call and webcast held the same day
Net loss of $49.2 million ($0.50 per share), including a $26.9 million non-cash warrant revaluation loss; cash, cash equivalents and short-term investments of $48.4 million at September 30, before the November offering; runway guidance into late Q4 2027 repeated. Q3 results release · Q3 Form 10-Q. The call had been announced to discuss the financial results and provide a general business update. Company release. Webcast page.
- November 18, 2026 · VOCERYQ conditional marketing authorization application to the EMACompleted · submission announced; EMA review ahead
INOVIO submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency for VOCERYQ in adults with RRP. The European Commission granted INO-3107 orphan drug designation in 2023, the EMA’s Committee for Advanced Therapies issued an Advanced Therapy Medicinal Product (ATMP) certification after reviewing chemistry, manufacturing and controls (CMC) and nonclinical data, and the CELLECTRA delivery device carries a CE mark in the EU. Submission is not approval; the release gives no review timetable. Company release.
- November 18, 2026 · 12:00 p.m. ET (5:00 p.m. GMT) · Jefferies Global Healthcare Conference, LondonPast date · presentation, investor event
Webcast presentation scheduled for that time, with a replay announced as available for 90 days; members of management also scheduled one-on-one meetings with investors. Company release.
- December 1, 2026 · 2:00–2:25 p.m. ET · Piper Sandler 38th Annual Healthcare Conference, New YorkScheduled · fireside chat, investor event
Webcast fireside chat, with replay available for 90 days; conference appearances are not data releases. Company release.
- Approximately 60 days from October 30 · Order and shipping availabilityCompany expectation in November 2 filing, repeated November 10
Full field deployment is anticipated in Q1 2027. A proposed confirmatory protocol is due by year-end 2026, with final alignment expected by mid-2027. These are planning windows, not confirmed trial completion dates. Company filing.
- Late Q4 2027 · Runway estimate in the November 6 prospectus supplementCompany estimate · includes the offering’s net proceeds
INOVIO expects the offering’s net proceeds plus existing cash and short-term investments to fund operating expenses and capital expenditures into the late fourth quarter of 2027, replacing the August forecast of late Q1 2027; the estimate rests on assumptions that may prove incorrect. The November 10 results release repeats it, including $10.9 million of warrant-exercise proceeds after September 30 and an estimated Q4 2026 operational net cash burn of about $21.0 million, and excluding VOCERYQ revenue. Final prospectus supplement · Q3 results release.
- No fixed collection date · VGXI judgment enforcementCollection and post-trial risks
The award should enter liquidity analysis only as cash is actually collected, with any changes in the judgment disclosed.
INO-3107 evidence and the accelerated-approval question
Evidence
32-patient RRP-001
The single-arm trial used each patient’s prior surgery history rather than a concurrent control. Follow-up observations support further assessment but do not create randomized comparative evidence.
Regulatory
Accelerated approval granted
The FDA granted accelerated approval on October 30, 2026. The pathway now requires post-approval trials to verify clinical benefit.
Competition
PAPZIMEOS is approved
The existing adult RRP therapy matters to the regulatory and commercial setting. Cross-trial response rates cannot establish head-to-head superiority.
The October 30 accelerated approval settles the review; the confirmatory trials and real-world use will test the clinical benefit. INOVIO regulatory and risk disclosure · Trial registry · FDA PAPZIMEOS information.
INO-3107 also depends on CELLECTRA delivery. The filing describes a historical single-use component manufacturing issue that the company believes it corrected, while further FDA review of the device and the Investigational New Drug (IND) application for the confirmatory protocol remained necessary. Drug, device and manufacturing requirements must be assessed together.
INO financing, share dilution and litigation claims
The November 5 preliminary prospectus supplement reports 110,181,507 common shares outstanding as of September 30, 2026, excluding 94,081,029 shares underlying historical warrants (exercise prices $1.10–$3.76), 3,674,528 option shares at a weighted average exercise price of $14.79, and restricted stock units. The November 5 pricing release described an offering of approximately $75 million gross, before underwriting discounts, commissions and expenses and before the underwriters’ option, which was exercised in full on November 6. The offering closed on November 9, 2026 (terms in chapter 10), and the Q3 Form 10-Q cover reports 187,306,884 common shares outstanding on November 10, 2026. Shares outstanding, shares issuable on exercise of warrants and other potential shares are distinct measures. Q3 Form 10-Q · Official pricing announcement · Preliminary prospectus.
Common shares increased from 68,996,647 at December 31, 2025 to 103,397,518 at August 10, 2026. The June warrant schedule plus July issuance total a historical 97,706,767 potential shares before later changes; they are not all automatically issued. The Q3 Form 10-Q reports 667,074 shares sold under the at-the-market (ATM) sales agreement in the first nine months of 2026 at a weighted average of $1.65, for $1.1M net, and $56.8M of remaining capacity at September 30; the ATM prospectus was suspended on April 1, 2026, so that amount is not committed funding or cash. Q3 Form 10-Q.
The $6.0M reported Q2 net loss included a $13.9M non-cash warrant revaluation gain; it should not substitute for the $39.6M first-half operating cash outflow. The securities and derivative cases concern disputed disclosure allegations, while the separate VGXI supply litigation produced a judgment with explicit collection risk. June Form 10-Q · October judgment release.
INOVIO Pharmaceuticals deep dive: the full analysis
The product, evidence, commercial plan and financial structure behind INO stock, as of November 17, 2026. The Merlintrader Research Library collects our dated biotech stock research reports.
01 INO stock scenarios after VOCERYQ approval
Merlintrader reading, November 17, 2026. The FDA approval and November financing are completed events. The scenarios now concern turning VOCERYQ into an accessible, commercially used treatment while meeting confirmatory obligations and managing the expanded share base. A favorable regulatory decision has changed the operating problem; it has not established the pace or profitability of adoption.
Bull scenario: a funded launch converts interest into use
The constructive path is that ordering and shipment start near the company-guided timetable, access arrangements support appropriate prescribing, and the clinical and device workflow is practical for treating centers. Confirmatory-study planning and the European application advance without materially disrupting launch resources. Revenue would add a source of funding that management excluded from its current runway estimate, while broader programs progress through documented partnerships.
Base scenario: commercial progress with spending ahead of receipts
A more measured scenario combines gradual launch adoption with investment in field deployment, distribution, reimbursement and post-approval work. An approved product can take time to generate collected cash. The financing provides runway under management’s assumptions, but quarter-end cash, net offering proceeds and future spending must retain their separate dates. Conference appearances can explain execution; they are not product-sales reports.
Bear scenario: access, uptake or obligations strain the plan
The cautious path is slower reimbursement or uptake, higher launch costs, competitive pressure, or a confirmatory program that requires more resources than planned. Existing warrants and other potential issuance can constrain per-share outcomes even if sales grow. Litigation proceeds may not arrive, and further funding could be needed before a sustainable business is established.
These are conditional business scenarios. They contain no security-price target or recommendation. Their observable tests are ordering availability, actual revenue and collections, cash spending, trial and regulatory commitments, and the number of shares or instruments issued to finance them.
FDA approval, October 30, 2026.
What would falsify this reading
Merlintrader reading. Four assumptions support the analysis: approval creates a real commercial opportunity; the financing supports management’s stated operating plan; confirmatory requirements remain executable; and clinical comparisons are interpreted within their study limits. Each has an observable failure condition.
- Launch timing or access materially misses the plan. Failure to make ordering and shipment available near the guided window, or evidence that reimbursement barriers prevent use, would weaken the commercial case.
- Spending outruns the funding assumptions. A materially faster cash burn, new major commitment or new financing need would require revisiting the runway. The estimate into late Q4 2027 is not guaranteed.
- Confirmatory work becomes more difficult. A different required study, an unresolved device or manufacturing issue, or failure to verify benefit could change both cost and the regulatory position.
- Evidence fails to support durable use. Real-world outcomes or additional studies inconsistent with the earlier evidence would change the clinical interpretation. Separate uncontrolled studies do not establish superiority over PAPZIMEOS.
- Capital or legal assumptions change. A modification of warrant terms, further issuance or an adverse development in judgment collection would affect the funding picture. A court award cannot substitute for cash actually received.
These conditions make the argument testable rather than treating FDA approval as the end of analysis. An approved product still needs a workable delivery, clinical and economic model.
02 What INOVIO does: DNA medicines and CELLECTRA
INOVIO develops DNA medicines intended to induce immune responses against HPV-related disease, cancers and infectious disease. Its approach uses plasmids encoding selected antigens, delivered with the CELLECTRA electroporation system. The scientific idea is to induce an antigen-specific immune response. That platform description does not by itself establish clinical benefit for every candidate or indication.
VOCERYQ, previously INO-3107, became the company’s first approved product on October 30, 2026 for adults with recurrent respiratory papillomatosis. RRP is a recurring disease involving growth of papillomas in the respiratory tract, often requiring repeated surgical procedures. Reducing the frequency of surgery is relevant to disease burden, but the evidence supporting an approval and the evidence required afterward must be distinguished.
Delivery is part of the treatment rather than an unrelated accessory. Clinicians, staff, device availability, training, product handling and reimbursement all affect whether an approved therapy can be delivered in routine practice. The historical manufacturing issue involving a single-use component should be read as a disclosed historical risk, while current requirements are governed by the approved product and the continuing regulatory obligations.
Merlintrader reading: INOVIO is moving from a development company into launch execution. Its remaining pipeline still contains investigational programs with different mechanisms, indications, partners and evidence. Approval of one product does not confer approval or commercial value automatically on the rest of that portfolio.
03 INO stock catalysts: launch, confirmatory work and Europe
The November 10 company update expects VOCERYQ to be available to order and ship approximately 60 days after October 30 approval, with full field deployment in the first quarter of 2027. These are company expectations. Neither window establishes that orders have already been received or that revenue will be recognized by a particular quarter-end.
The company expects a draft confirmatory-study protocol to be submitted by year-end 2026 and aims for final alignment by mid-2027. Protocol submission, regulatory agreement, enrollment, completion and verification of benefit are separate milestones. The European step planned for year-end 2026 came on November 18, 2026, when INOVIO announced the submission of a Conditional Marketing Authorization application for VOCERYQ to the EMA; submission does not itself establish European approval, and the release gives no review timetable.
The Jefferies presentation scheduled for November 18 and the December 1 Piper Sandler fireside chat are investor events announced November 11. They are opportunities to explain launch and operating plans, not automatically new clinical readouts. The next results release will also have to distinguish the September financial baseline from the November financing and subsequent expenditure.
Merlintrader reading: the next phase is a sequence of execution checks rather than one pending FDA decision date. Changes to shipping availability, the confirmatory plan, geographic rights, access or funding should be dated and attributed individually.
04 VOCERYQ accelerated approval: what changed on October 30
The FDA granted accelerated approval to VOCERYQ for adults with RRP on October 30, 2026. This closes the review that preceded the approval. The agency’s decision is the relevant current status; acceptance for review, completion of inspections and a preliminary concern in a file-acceptance letter were prior milestones, not competing descriptions of today’s approval.
The FDA announcement describes evidence of reduced surgical intervention in an open-label study. Among the 26 adults who had at least three procedures in the year before treatment, seven, or 27%, needed no surgery in the first year after treatment. That subgroup and denominator differ from several company-reported results across the full 32-person study or the 28-person retrospective follow-up. The numbers should retain their original population and window.
Accelerated approval rests on an endpoint judged reasonably likely to predict clinical benefit, with post-approval trials required to confirm it. Approval is therefore a completed regulatory decision accompanied by continuing obligations. It does not mean that the original study became randomized, that a comparative advantage over another approved treatment has been proven, or that confirmatory evidence is already complete.
Merlintrader reading: the correct analytical balance recognizes both the significance of the first approval and the work still required. Launch uptake, the confirmatory design and eventual results, and manufacturing and device execution can each change the operating outlook. The presence of an approved competitor makes practical treatment selection and access important without reversing the fact of approval.
FDA decision and supporting evidence, October 30, 2026.
Q3 regulatory and risk discussion.
The Q3 filing says INOVIO and the FDA agreed that a confirmatory study should enroll at least 50 adult and pediatric patients with RRP who required three or more surgical interventions in the preceding twelve months. The company still expected to submit a proposed protocol by year-end 2026 and reach final protocol alignment by mid-2027. Those design and timing statements do not establish that enrollment or confirmation of benefit is complete; the approved indication remains adults with RRP. Q3 Form 10-Q: confirmatory-study discussion.
05 RRP-001: interpreting the original 32-person study
The pivotal evidence is one trial, registered as NCT04398433. Its design deserves to be stated exactly, because endpoint selection, study design and the total evidence package all matter to regulatory interpretation.
| Feature | As registered | What follows · Merlintrader reading |
|---|---|---|
| Design | Phase 1/2, open-label, multicenter, single-arm. No placebo and no comparator. | Each patient’s own prior year is the control. Open-label single-arm designs cannot separate drug effect from regression to the mean, from natural fluctuation in a disease known to wax and wane, or from the effect of the baseline debulking surgery every patient received. |
| Enrollment | 32 participants at eleven United States sites, from Mayo Clinic Arizona and Johns Hopkins to Cincinnati Children’s and Baylor. Minimum age eighteen. Started October 7, 2020; completed December 15, 2022. | The registered study is completed. Its size limits precision; completion of this trial does not remove the possibility of additional FDA evidence requirements or future confirmatory work. |
| Primary outcome | The percentage of participants with at least one treatment-emergent adverse event and serious treatment-emergent adverse events, from first dose through 30 days after the last, roughly to week 13. | The primary endpoint was safety. The efficacy measure everyone quotes is a secondary outcome. A safety-primary early-phase design requires careful interpretation of the efficacy evidence; it does not become randomized comparative evidence because the product subsequently received accelerated approval. |
| The efficacy outcome | Change in the number of RRP surgical interventions in the year following day 0 compared with the year before, assessed to week 52; plus the percentage of participants by percent reduction, and change in RRP staging assessment score on a modified Derkay tool scored 0 to 179. | A pre-specified, clinically concrete endpoint — how many operations a patient needed — measured without a concurrent control group. The FDA subsequently granted accelerated approval; the endpoint description alone does not remove the need to verify benefit after approval. |
| Entry requirement | Histologically documented HPV-6 or HPV-11 positive papilloma, and at least two RRP surgical interventions in the year prior to and including day 0. | The population was selected for recent frequent surgery, so regression to the mean and natural variation are important potential alternative explanations in a historical comparison. The design cannot quantify their contribution separately from treatment. |
The results, as the company reports them
- 81.3% (26 of 32) had a decrease in the number of surgical interventions in the year after administration compared with the prior year.
- 28.1% (9 of 32) required no surgical intervention during or after the dosing window.
- Patients had a median of four surgeries in the year before dosing, with an overall range of two to eight; after dosing there was a statistically significant median decrease of three interventions, with a 95% confidence interval of −3 to −2.
- Treatment generated activated CD4 and CD8 T cells with lytic potential, with responses still present at week 52.
- INO-3107 was well tolerated, with mostly Grade 1 treatment-emergent adverse events such as injection-site pain and fatigue.
- INOVIO reports that clinical response was not dependent on HPV viral load, molecular subtype or other measured elements of the papilloma microenvironment; this is an exploratory observation in the study population.
One point of precision that a careful reader should carry forward: the company presents these figures across shifting denominators — 32 in the original trial, 28 in the retrospective follow-up, 23 described as evaluable in one year-two cut. Each figure is attributable and is given here with its denominator, but the percentages are not comparing identical populations and do not form a single clean curve.
The observed reduction in surgery is clinically relevant to the disease burden, but its attribution to INO-3107 remains limited by the uncontrolled design. A handful of patients moves the percentages materially in a study this size. The FDA assesses the entire application, including the evidence supporting benefit and the requirements of the requested approval pathway. The findings support a potential treatment effect; they do not alone prove its size relative to natural fluctuation or other influences.
06 Durability: follow-up, denominators and uncertainty
The follow-up adds observations beyond the first year, which matters for a chronic disease. It is not a complete three-year result in every original participant: RRP-002 is retrospective, includes 28 of the original 32 patients and reports partial third-year data at a median follow-up of 2.8 years.
In August 2025, data from a retrospective study designated RRP-002 were published in The Laryngoscope. RRP-002 included 28 of the 32 participants from RRP-001 and evaluated them two and three years after initial dosing.
| Measure | Year 1 | Year 2 | What the comparison is worth · Merlintrader reading |
|---|---|---|---|
| Complete response — no surgery required | 28% (9 of 32) | 50% (14 of 28) | Fourteen of 28 follow-up participants required no surgery during year two. The first-year percentage uses all 32 original participants; the two headline percentages have different denominators. |
| Objective response — a 50 to 100% reduction in surgeries | 72% (23 of 32) | 86% (24 of 28) | The June 2026 Form 10-Q, filed in August, gives both denominators. These headline rates describe overlapping, not identical, populations and are not a randomized longitudinal comparison. |
| Mean number of surgeries a year | 1.7 | 0.9 | Against 4.1 in the 52 weeks before treatment, a 78% reduction in mean annual surgeries at year two. The pre-treatment figure has n=32 and the year-two figure n=28. |
| Patients continuing to need at least one fewer surgery | 81% (26 of 32) | 91% (21 of 23 evaluable) | The 23-patient denominator here is the company’s own and is smaller than the 28 used for the other year-two figures. The direction is consistent; the base is not. |
| Safety | One serious treatment-emergent adverse event (acute cholecystitis) in 1 of 32 participants through 30 days after the last dose, per the registered RRP-001 results | No serious adverse events and no long-term safety concerns identified in the retrospective follow-up | Over a period in which the median follow-up reached 2.8 years. The filing reports no serious adverse events or long-term safety concerns identified in that follow-up; a small study cannot exclude uncommon risks. |
The company reported a continuing trend toward fewer surgeries in partial third-year data at a median follow-up of 2.8 years. This is distinct from the 50% no-surgery rate during year two. Its statement that only two patients had not yet responded accompanies the 21-of-23 evaluable analysis; it is not a claim that 30 of all 32 original patients had responded at that time.
Two things to hold against that. RRP-002 is retrospective, which means the data were assembled after the fact from patients already known to have been treated, with all the selection and ascertainment problems that implies — and four of the original 32 are not in it. And the comparator is still the pre-treatment year, three years earlier, in a disease whose natural history in an individual patient over three years is not a straight line.
The durability observations make the clinical case more informative than a single one-year comparison. They remain compatible with a sustained treatment effect, but the absence of a concurrent untreated group means they cannot exclude natural fluctuation, regression to the mean, differences in surgical decisions or follow-up selection. Four original participants were not in the retrospective cohort, and year-three observations were incomplete. Persistence of an observed reduction is therefore supportive evidence, not proof that baseline surgery or other study artifacts have been ruled out. June 2026 Form 10-Q 2025 Form 10-K
07 PAPZIMEOS and VOCERYQ: comparison without a head-to-head trial
PAPZIMEOS was approved for adult RRP in August 2025. Its existence is relevant to clinical choice, treatment workflow, reimbursement and INOVIO’s launch plan. VOCERYQ’s October 2026 approval supplies another approved option; it does not demonstrate which treatment produces a better outcome in a particular patient.
The studies used different baseline requirements, populations, observation windows and definitions. The original RRP-001 trial enrolled patients with at least two procedures in the preceding year including the baseline procedure, while the PAPZIMEOS efficacy population had a different surgery-frequency requirement. A no-surgery outcome during year two is not identical to a response maintained continuously from an earlier time point through two years.
The delivery and procedure requirements also matter. PAPZIMEOS prescribing information includes surgical debulking before treatment and removal of visible disease at specified subsequent administrations when present. INOVIO has described its own regimen as differentiated. Such a difference is not a guarantee that every patient avoids rescue surgery, and it cannot be converted into a comparative efficacy estimate without an appropriate study.
Merlintrader reading: a clinician may consider the approved labels, disease history, delivery workflow and patient circumstances. From an operating perspective, INOVIO must demonstrate that its product can be prescribed, delivered and reimbursed in that environment. Cross-trial numerical rankings cannot replace those tests or supply a reliable market-share assumption. Preventive HPV vaccination and treatment of established RRP address different clinical questions.
08 INOVIO earnings, cash burn and the funding horizon
The Q3 2026 results report $48.4 million of cash, equivalents and short-term investments at September 30, before the November offering. Operating activities used $54.9 million in the first nine months. The quarter’s $49.2 million net loss included a $26.9 million noncash warrant-liability revaluation loss. That accounting movement cannot be treated as an equivalent cash payment.
The November 9 closing generated approximately $80.5 million of net offering proceeds. The November 10 update also includes $10.9 million of warrant-exercise proceeds after September 30 in the funding assessment. These later inflows do not change the historical September financial statements. Adding them mechanically to September cash would still omit intervening spending and other cash movements, so no such total is presented as a current bank balance.
Management expects resources to support operations into late Q4 2027, excluding VOCERYQ revenue, using assumptions that include estimated Q4 2026 operational net cash burn of about $21 million. The Form 10-Q retains substantial doubt about continuing as a going concern beyond the fourth quarter of 2027. The cash guidance and the warning describe different aspects of the same funding horizon rather than cancelling each other out.
Merlintrader reading: launch and confirmatory spending may differ from the first nine months’ average. The relevant comparison is actual expenditure and collections against the plan. A higher noncash warrant loss can make reported earnings look worse without equivalent cash burn, while stock compensation and issuance can still affect owners. Commercial revenue, recognized revenue and cash collection also need to be distinguished once product sales begin.
09 Debt, commitments and the VGXI judgment
The funding analysis must include obligations beyond a single headline cash or debt measure. Leases, manufacturing and commercial arrangements, post-approval clinical work and licensed-program commitments can require expenditure before a profitable launch. Contingent amounts should be distinguished from liabilities already recorded and from unconditional cash payments due.
On October 20, 2026 INOVIO announced a favorable VGXI-related judgment of $80,416,101. The company expressly warned that collection of some or all of the award may be limited by the defendants’ financial condition, and that post-trial proceedings or appeal could alter the outcome. The judgment is a legal claim rather than money available to pay launch costs.
The separate shareholder and derivative matters concern disputed allegations. Their procedural status and financial implications should be read from the latest filing without treating allegations as established misconduct or the favorable supply judgment as resolution of every unrelated case. An exclusive-forum bylaw determines specified forums for claims; it does not decide the merits of a pending dispute.
Merlintrader reading: an eventual collection could improve liquidity when it actually occurs, but its amount and timing cannot be assumed. The operating plan should be understood using reported resources and management’s guidance, with legal recoveries kept separate. Any new payment, settlement, appeal decision or material commitment would require a fresh dated assessment.
10 INO share dilution: closed offering, warrants and ATM
The Q3 cover reports 187,306,884 common shares outstanding on November 10, 2026. This is the disclosed post-offering basic count, rather than the earlier September 30 count of 110,181,507. Prospectus illustrations of shares after the original offering, with or without the underwriter option, were assumptions at their publication date; they should not replace the later filed actual count.
The November 9 closing comprised 69,461,520 common shares at $1.05, including the 10,714,285 option shares, and 12,681,337 pre-funded warrants sold at $1.049. Those are contractual financing prices. The approximately $80.5 million figure is net proceeds including the exercised option, rather than the original gross headline before its exercise.
The September 30 warrant schedule covered 94,081,029 potential shares from historical issues, with exercise prices from $1.10 to $3.76. Subsequent exercises and the November pre-funded warrants belong to different dated parts of the capital structure. Issued common stock, outstanding warrants, employee awards and shares merely reserved for future grants should not be counted as the same category.
The Q3 filing reports 667,074 shares sold through the ATM during the first nine months at a weighted average of $1.65 for approximately $1.1 million net. Remaining capacity was $56.8 million at September 30, but the ATM prospectus had been suspended since April 1. That capacity is not committed funding or cash already received.
Merlintrader reading: the financing materially changes the resource base and the ownership denominator. Funding a launch can be operationally constructive while diluting existing claims. The assessment must therefore follow both business progress and capital issued.
Q3 share count, subsequent offering and warrant disclosures.
11 Management, governance and the broader pipeline
The company’s operating plan prioritizes VOCERYQ while seeking partnerships or other arrangements for additional DNA-medicine programs. Its broader candidates differ in clinical stage, target disease, trial sponsor and contractual economics. A partner supplying a checkpoint inhibitor or an academic center sponsoring a study does not demonstrate that INOVIO has no remaining cost or that a partnership guarantees development success.
The Q3 filing describes INO-3112 in HPV-related oropharyngeal cancer, INO-5412-related work in glioblastoma, VGX-3100 in other HPV-associated disease settings, and DNA-encoded protein and antibody technologies. These remain separate from the approved RRP product. Early activity in a combination trial cannot be transferred to a different candidate, tumor type or commercial indication.
On November 17, 2026 INOVIO disclosed the appointment of Jeffrey Libson to its board, effective November 13, expanding the board from eight to nine members and adding him to the Finance Committee. He had served as an adviser since January 2025. The appointment adds governance capacity; it is not evidence of a financing transaction, acquisition or independently validated commercial forecast.
Merlintrader reading: the execution test is whether management can coordinate product availability, patient access, distribution, confirmatory work and a resource-constrained pipeline. Compensation, board structure and partnership terms deserve attention as inputs to that task. Progress should be judged on disclosed actions and results rather than assuming either success or failure from the company’s earlier development history.
November 17 Form 8-K: board appointment effective November 13.
12 INO ownership, short interest and sentiment
Four Schedule 13G reports filed November 16, 2026 illustrate why the event date matters. ADAR1 reports 6,429,624 beneficially owned securities as of June 30, including 2,143,910 common shares and 4,285,714 shares underlying warrants, with a filed percentage of 7.4%. Tang Capital Management, LLC, filing jointly with Kevin Tang and affiliated Tang Capital entities, reports 17,978,200 beneficially owned securities for a November 6 event, comprising 17,659,259 common shares and 318,941 currently issuable pre-funded-warrant shares, with a filed 9.99% position and an ownership blocker affecting exercisability. These are different securities and reference dates.
Alyeska’s September 30 position is 3,428,572 shares and 3.32%; the manager, general partner and controlling person report jointly, so their figures must not be added together as three independent holdings. Highbridge’s filing covers a September 30 event and reports a percentage subject to an ownership limitation, with a denominator referencing the earlier August share count. A nominal right to acquire shares can exceed what is presently exercisable under a blocker.
Merlintrader reading: these filed percentages describe each report’s methodology and reference date. They are not recalculated using the November 10 basic count and are not presented as four current percentages of one identical share base. A filing after the financing may still report a pre-financing ownership event. Beneficial ownership is not proof of open-market conviction buying or access to undisclosed commercial results.
ADAR1 Schedule 13G, filed November 16, 2026 · Tang Capital Management Schedule 13G, filed November 16, 2026 · Alyeska Schedule 13G/A, filed November 16, 2026 · Highbridge Schedule 13G/A, filed November 16, 2026.
Institutional beneficial ownership is a dated filing measure, particularly important after a large equity financing. A percentage filed using an earlier denominator cannot be interpreted as a current percentage after the November issuance. Voting power, dispositive power, common stock and rights to acquire shares may be treated differently within a reporting person’s disclosure.
Nasdaq’s October 30, 2026 settlement data report 22,100,943 shares short, associated average daily volume of 12,147,378 and approximately 1.82 days to cover. These are delayed settlement-based observations before the November offering closed. They do not describe the post-financing float or guarantee the ability to execute a position at a particular moment.
Merlintrader reading: investor positioning can influence volatility without establishing knowledge of future sales, confirmatory results or regulatory decisions. Days to cover is a ratio using a volume denominator, not a countdown to forced buying. Retail discussions may identify questions worth verifying, while the primary evidence remains the FDA decision, company filings and actual operating disclosures. An acquisition claim or a new strategic investment requires its own attributable announcement.
13 Red flags and the Merlintrader assessment
Merlintrader reading, November 17, 2026. INOVIO has moved beyond a pending approval decision to a funded but unproven commercial launch. The first approved product and completed financing are substantial changes, while commercial uptake, confirmatory obligations and dilution remain central constraints. Approval changes the evidence record; it does not turn all future assumptions into facts.
The main clinical limitation is still the uncontrolled evidence base and the need to verify benefit. The durability follow-up is informative but retrospective, with different denominators and incomplete third-year observations. Cross-trial comparisons with PAPZIMEOS cannot establish relative efficacy or a guaranteed commercial preference.
The principal financial limitation is the relationship between cash, spending and ownership. The company guides into late Q4 2027 under stated assumptions, while retaining a going-concern warning beyond that horizon. Launch costs and post-approval work can consume resources before sales become collected cash. The judgment should not be treated as an additional bank balance, and remaining equity instruments can affect the number of ownership claims.
The Health Score below is 2.40 out of 5 after reassessment on November 18. It is a weighted assessment of balance sheet, catalyst, dilution, trading liquidity and execution, rather than an approval probability or security-return forecast. A completed financing can improve funding while leaving the dilution pillar weak. An FDA decision can improve regulatory certainty while leaving commercial execution unfinished.
The strongest future evidence would be documented product availability, appropriate use supported by access, a workable confirmatory plan and disciplined spending. Contrary evidence would require revising the interpretation. These are business and evidence checkpoints intended to explain the company, without recommending an investment transaction.
Merlintrader Health Score · INO
2.40out of 5
Merlintrader assessment, November 10, 2026, after the third-quarter results and Form 10-Q confirming the November 9 closing of the offering (balance sheet 2/5): 2×30% + 3×30% + 1×20% + 4×10% + 3×10% = 2.40/5. This measures robustness; it is not an FDA probability, a target price or an investment recommendation. Reassessed November 17, 2026 after the board appointment disclosed that day: pillar marks 2/3/1/4/3, weighted total 2.40; launch and confirmatory execution remain ahead. Reassessed November 18, 2026 after the EMA submission announced that day: catalyst and execution pillars reviewed, marks unchanged at 2/3/1/4/3; 2×30% + 3×30% + 1×20% + 4×10% + 3×10% = 2.40/5. The submission opens a European review without changing funding or dilution.
INO red flags
- The accelerated approval depends on post-approval trials that must verify clinical benefit.
- Launch uptake, pricing and access are untested, and an approved competitor is already on the market.
- Uncontrolled studies and cross-trial comparisons have material evidence limits.
- Manufacturing, device, labeling and confirmatory requirements can affect the outcome and cost.
- The Q3 Form 10-Q keeps substantial doubt about continuing as a going concern beyond the fourth quarter of 2027; the runway estimate excludes VOCERYQ revenue and rests on assumptions that may prove incorrect.
- After the offering closed on November 9, 2026, shares outstanding were 187,306,884 on November 10 versus 110,181,507 at September 30, before exercise of 12,681,337 pre-funded warrants, other warrants and equity awards.
- The VGXI judgment may not be collected in full or remain unchanged.
- Disclosure litigation contains allegations, not findings.
INO Stock FAQ: INOVIO Pharmaceuticals Questions Answered
When is the next INOVIO INO stock catalyst after VOCERYQ approval?
After the Jefferies presentation scheduled for November 18, 2026, the next scheduled INOVIO investor event is a December 1 Piper Sandler fireside chat. On November 18 INOVIO announced the submission of a Conditional Marketing Authorization application for VOCERYQ to the European Medicines Agency; EMA review lies ahead (EMA submission release). Company plans include VOCERYQ ordering about 60 days after October 30 approval, a proposed confirmatory-study protocol by year-end 2026, and full field deployment in Q1 2027. These are different milestones; conference appearances are not clinical readouts. Investor events · Launch and regulatory plans.
Was INOVIO’s INO-3107 approved by the FDA?
Yes: the FDA granted accelerated approval to VOCERYQ, previously INO-3107, on October 30, 2026 for adults with recurrent respiratory papillomatosis. Approval rests on reduced surgical intervention, an intermediate endpoint reasonably likely to predict clinical benefit. Post-approval trials must verify that benefit; the product is administered using CELLECTRA 5PSP. Approval, evidence basis and delivery device.
How much cash does INOVIO have and how long should it last?
INOVIO reported $48.4 million of cash, equivalents and short-term investments at September 30, 2026, before its November financing. The offering closed November 9 with approximately $80.5 million net proceeds; warrant exercises after September 30 added $10.9 million. Management guides into late Q4 2027, excluding VOCERYQ revenue and assuming about $21 million operational net cash burn in Q4 2026. The Q3 filing retains substantial doubt about continuing as a going concern beyond Q4 2027. Q3 filing · Cash guidance.
Can INOVIO’s warrants and ATM financing dilute INO stock?
Yes: warrants, pre-funded warrants, equity awards and further financing can dilute INO stock. INOVIO reported 187,306,884 common shares on November 10, 2026, after the November 9 offering closing. Warrants covered 94,081,029 potential shares at September 30; the November offering separately included 12,681,337 pre-funded warrants. Remaining ATM capacity was $56.8 million at September 30, with its prospectus suspended since April 1. Potential securities are distinct from issued shares. Q3 shares, warrants and financing.
When does INOVIO report its next earnings?
INOVIO reported third-quarter 2026 results on November 10, 2026; as of November 18, 2026 the company had not announced its next quarterly results date. The reported quarter ended September 30. The company held its results call on November 10. The investor appearances scheduled for November 18 and December 1 are separate events. Results release · Investor conferences.
What does INOVIO Pharmaceuticals do?
INOVIO develops DNA medicines designed to stimulate immune responses against HPV-related disease, cancer and infectious disease. Its first approved product, VOCERYQ, treats adults with recurrent respiratory papillomatosis and uses the CELLECTRA electroporation device for delivery. The company is moving from development into commercial launch while maintaining a broader investigational pipeline. Approved product and delivery. Company description, October 20 release. Commercial launch plans.
Is INOVIO’s VGXI judgment available cash?
No: INOVIO’s October 20, 2026 announcement reports an $80,416,101 judgment, while explicitly warning that the defendants’ financial condition may prevent collection of some or all of it. Post-trial motions or appeal may also change the award. The judgment therefore cannot be added to a cash balance as if already collected. Judgment and collection risks.
Did INOVIO’s completed inspections prove INO-3107 would be approved?
No: the inspection milestone described in INOVIO’s August 2026 filing did not by itself establish that every clinical, manufacturing and device requirement had been satisfied. The actual approval is the FDA’s October 30 decision. Even after that decision, commercial execution and the required confirmatory studies remain separate obligations. Pre-approval inspection disclosure. Actual approval and remaining studies.
Primary sources
- November 18, 2026 — VOCERYQ Conditional Marketing Authorization application submitted to the European Medicines Agency (company release)
- November 11, 2026 — Jefferies Global Healthcare Conference presentation (November 18) and Piper Sandler Healthcare Conference fireside chat (December 1) (company release)
- November 10, 2026 — Form 10-Q for the quarter ended September 30, 2026: cash, going concern, offering closing and shares outstanding
- November 10, 2026 — INOVIO reports third quarter 2026 financial results and recent business highlights
- November 10, 2026 — Form 8-K, exhibit 99.1: third-quarter results release
- November 9, 2026 — Form 8-K: underwriting agreement, full exercise of the underwriters’ option, about $80.5 million expected net proceeds and runway statement
- November 6, 2026 — Final prospectus supplement (Form 424B5): offering terms, net proceeds, post-offering shares and dilution
- November 5, 2026 — INOVIO prices approximately $75 million offering
- November 5, 2026 — INOVIO announces proposed offering
- November 5, 2026 — Preliminary prospectus supplement (Form 424B5)
- November 5, 2026 — Form 8-K: preliminary September 30 cash estimate
- November 2, 2026 — INOVIO to report third quarter 2026 financial results on November 10
- FDA VOCERYQ approval announcement
- June Form 10-Q
- VGXI judgment release
- Exclusive-forum Form 8-K
- September conference announcement
- July financing Form 8-K
- RRP-001 registry
- FDA PAPZIMEOS information
- Nasdaq historical market data
- Nasdaq short interest
- ADAR1 Schedule 13G, filed November 16, 2026
- Tang Capital Management Schedule 13G, filed November 16, 2026
- Alyeska Schedule 13G/A, filed November 16, 2026
- Highbridge Schedule 13G/A, filed November 16, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $INO or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, clinical trial registries and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
INOVIO received FDA accelerated approval for VOCERYQ (INO-3107) on October 30, 2026, but has no reported product revenue yet. Continued approval depends on a confirmatory program, the company faces an approved competitor in its lead indication, and it has stated substantial doubt about its ability to continue as a going concern. Commercial launch, confirmatory-trial results and any further equity financing would each have material consequences. Companies at this stage can lose all of their value. Where this page describes litigation, it reports allegations that have not been tested and adopts none of them.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



